Solasia Pharma K.K Toekomstige groei
Future criteriumcontroles 5/6
Solasia Pharma K.K is forecast to grow earnings and revenue by 69.2% and 39.5% per annum respectively while EPS is expected to grow by 69.2% per annum.
Belangrijke informatie
69.2%
Groei van de winst
69.2%
Groei van de winst per aandeel
| Biotechs winstgroei | 10.7% |
| Inkomstengroei | 39.5% |
| Toekomstig rendement op eigen vermogen | n/a |
| Dekking van analisten | Low |
| Laatst bijgewerkt | 18 Oct 2024 |
Recente toekomstige groei-updates
Recent updates
Winst- en omzetgroeiprognoses
| Datum | Inkomsten | Inkomsten | Vrije kasstroom | Geldmiddelen uit operationele activiteiten | Gem. Aantal analisten |
|---|---|---|---|---|---|
| 12/31/2026 | 2,829 | 91 | 142 | 203 | 1 |
| 12/31/2025 | 1,717 | -787 | -937 | -753 | 1 |
| 12/31/2024 | 1,657 | -538 | -544 | -501 | 1 |
| 6/30/2024 | 160 | -1,286 | -503 | -503 | N/A |
| 3/31/2024 | 408 | -1,181 | -746 | -746 | N/A |
| 12/31/2023 | 617 | -1,112 | -359 | -359 | N/A |
| 9/30/2023 | 1,209 | -1,267 | -1,240 | -1,240 | N/A |
| 6/30/2023 | 1,432 | -1,738 | -1,839 | -1,441 | N/A |
| 3/31/2023 | 1,199 | -2,174 | -1,681 | -1,282 | N/A |
| 12/31/2022 | 1,092 | -2,548 | -2,477 | -2,074 | N/A |
| 9/30/2022 | 761 | -2,416 | -1,980 | -1,520 | N/A |
| 6/30/2022 | 470 | -2,331 | -2,380 | -2,214 | N/A |
| 3/31/2022 | 581 | -2,437 | -2,558 | -2,392 | N/A |
| 12/31/2021 | 559 | -2,478 | -2,636 | -2,473 | N/A |
| 9/30/2021 | 450 | -4,301 | -2,711 | -2,595 | N/A |
| 6/30/2021 | 492 | -4,249 | -2,478 | -2,360 | N/A |
| 3/31/2021 | 389 | -4,252 | -2,857 | -2,688 | N/A |
| 12/31/2020 | 454 | -4,127 | -2,960 | -2,789 | N/A |
| 9/30/2020 | 1,306 | -2,132 | -1,911 | -1,699 | N/A |
| 6/30/2020 | 1,420 | -2,046 | -1,788 | -1,676 | N/A |
| 3/31/2020 | 1,405 | -1,838 | -1,045 | -980 | N/A |
| 12/31/2019 | 1,310 | -1,867 | -1,560 | -828 | N/A |
| 9/30/2019 | 499 | -2,561 | -2,607 | -1,846 | N/A |
| 6/30/2019 | 364 | -2,599 | -2,751 | -1,969 | N/A |
| 3/31/2019 | 372 | -2,662 | -3,250 | -2,381 | N/A |
| 12/31/2018 | 318 | -2,422 | -2,580 | -2,323 | N/A |
| 9/30/2018 | 111 | -2,129 | -2,536 | -2,238 | N/A |
| 6/30/2018 | 489 | -1,378 | -1,965 | -1,440 | N/A |
| 3/31/2018 | 414 | -1,086 | N/A | -1,169 | N/A |
| 12/31/2017 | 410 | -1,007 | N/A | -911 | N/A |
| 9/30/2017 | 709 | -493 | N/A | N/A | N/A |
| 12/31/2016 | 501 | -762 | N/A | -464 | N/A |
| 12/31/2015 | 229 | -917 | N/A | N/A | N/A |
| 12/31/2014 | 11 | -677 | N/A | N/A | N/A |
Toekomstige groeivoorspellingen analisten
Verdiensten versus spaarpercentage: 4597 is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (0.3%).
Winst versus markt: 4597 is forecast to become profitable over the next 3 years, which is considered above average market growth.
Hoge groeiwinsten: 4597 is expected to become profitable in the next 3 years.
Omzet versus markt: 4597's revenue (39.5% per year) is forecast to grow faster than the JP market (4.2% per year).
Hoge groei-inkomsten: 4597's revenue (39.5% per year) is forecast to grow faster than 20% per year.
Groeiprognoses winst per aandeel
Toekomstig rendement op eigen vermogen
Toekomstige ROE: Insufficient data to determine if 4597's Return on Equity is forecast to be high in 3 years time